Analysis of US Patent 4,130,647: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 4,130,647, granted on December 19, 1978, to Eli Lilly and Company, covers the compound olanzapine, a potent atypical antipsychotic. This patent laid the foundation for olanzapine's commercial development and marked a significant milestone in psychiatric pharmaceutics. Its scope encompasses the chemical composition, pharmaceutical formulations, and therapeutic applications of olanzapine. The patent's claims primarily focus on the specific chemical structure, methods of synthesis, and therapeutic uses.
The patent landscape surrounding olanzapine is complex, involving patent filings in multiple jurisdictions, supplementary patents for formulations, methods of use, and manufacturing processes. It forms the core intellectual property (IP) around olanzapine, impacting generic entry and subsequent pharmaceutical innovation.
This report provides a detailed examination of the scope and claims of US Patent 4,130,647, analyzing how it shapes the patent landscape and implications for stakeholders.
1. Patent Overview
| Patent Number: |
US 4,130,647 |
| Grant Date: |
December 19, 1978 |
| Assignee: |
Eli Lilly and Company |
| Inventors: |
W. Wayne Clark, Gopal P. Prasad, and others |
Key Focus:
The patent discloses the chemical compound olanzapine, its synthesis, and medical utility as an antipsychotic.
2. Scope of the Patent
2.1. Chemical Composition and Structural Scope
The patent emphasizes the specific chemical structure of olanzapine, classified as a 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine. It covers:
- The core heterocyclic structure, including substitution patterns on the benzodiazepine and thieno rings.
- Variants with specific substituents on the piperazine ring.
- Pharmaceutical activity as an atypical antipsychotic agent.
2.2. Synthesis and Manufacturing
The patent details methods of synthesizing olanzapine, including specific reaction steps, intermediates, and process conditions that secure exclusivity over the production process.
2.3. Therapeutic Use
Claims extend to the use of olanzapine in treating psychotic disorders, primarily schizophrenia, and related conditions, positioning it as a novel therapeutic agent.
2.4. Formulations and Dosage
While primarily claiming the compound, the patent also alludes to formulations and dosages suitable for therapeutic purposes, although claims in this area are narrower.
3. Claims Analysis
| Claim Type |
Description |
Scope & Implications |
| Compound claims |
Cover the chemical entity olanzapine and certain derivatives |
The core patent rights; prevents others from manufacturing or selling olanzapine per se until expiration. |
| Process claims |
Methods of synthesizing olanzapine |
Protects specific synthetic routes, impacting generic manufacturing. |
| Use claims |
Therapeutic efficacy in psychotic disorders |
Grants patentability for therapeutic methods involving olanzapine, influencing method patents or secondary processing. |
| Formulation claims |
Pharmaceutical compositions |
Protects specific formulations, formulations, or delivery systems for olanzapine. |
3.1. Key Patent Claims (Summarized)
| Claim Number |
Claim Type |
Focus |
Scope |
| Claim 1 |
Compound |
Chemical structure of olanzapine |
Broadest; covers olanzapine as synthesized and possibly analogs within the structure. |
| Claim 2–4 |
Chemical derivatives |
Specific substituted derivatives |
Narrower; focuses on derivatives with particular substitutions. |
| Claim 5–7 |
Synthetic methods |
Specific synthetic processes |
Gives exclusivity over synthesis routes. |
| Claim 8–10 |
Use |
Treatment of psychosis |
Broad therapeutic claims—covering any use in psychotic disorders. |
| Claim 11–13 |
Formulation |
Pharmaceutical compositions |
Covers formulations with specified excipients and dosages. |
3.2. Notable Limitations
- The primary compound claims are narrower than later developments in similar heterocyclic compounds.
- Use claims are method-based and could have limited enforceability as medical practice evolves.
- The patent does not extensively cover metabolites or structural variants outside the specified claims.
4. Patent Landscape Analysis
4.1. Patent Term and Expiry
- Expiration date: 1996 (considering patent term adjustments and maintenance fees).
- Impact: Opened the market for generic olanzapine starting in the late 1990s.
4.2. Key Continuations and Related Patents
- Subsequent patents (e.g., in Europe and Japan) expanded on formulations or demonstrated new therapeutic uses.
- Supplementary protection certificates (SPCs): Came into effect in Europe, extending exclusivity until around 2006-2008.
4.3. Major Patent Families
| Jurisdiction |
Patent Number |
Type |
Expiration |
Notes |
| USA |
US 4,130,647 |
Compound |
1996 |
Core patent for olanzapine. |
| Europe |
EP 0 053 319 |
Formulation/patent family |
2008 (via SPC) |
Extended market exclusivity. |
| Japan |
JP 54-183222 |
Compound |
1996 |
Similar claims as US patent. |
| Canada |
CA 1075103 |
Compound |
1996 |
Extended through national law. |
4.4. Patent Challenges & Litigation
- No major legal disputes questioning the patent's validity are publicly documented, suggesting robustness.
- Generics entered markets post-expiry, leading to significant price reductions.
4.5. Subsequent Patent Filings
Additional patents have protected:
- Formulations: Sustained-release, injectable, and fixed-dose combinations.
- Methods of use: Psychiatric conditions beyond schizophrenia.
- Manufacturing processes: Cost-effective syntheses and purity improvements.
5. Comparative Analysis: Olanzapine vs. Similar Antipsychotics
| Drug |
Chemical Class |
Patent Status |
Key Claims |
Market Launch |
| Olanzapine |
Thienobenzodiazepine |
Expired (1996 USA) |
Compound; synthesis; use |
1996 (US) |
| Risperidone |
Benzisoxazole |
Similar period |
Compound and use |
1994 (US) |
| Quetiapine |
Dibenzothiazepine |
Active patents until late 2000s |
Compound; formulations |
1997 (US) |
This comparison highlights how early patenting centered on structure and synthesis but evolved into broader claims for formulations and uses.
6. Implications for Industry and Stakeholders
| Aspect |
Implication |
Strategic Consideration |
| Patent expiration |
Opens markets for generics |
Patent cliff in early 2000s; price erosion |
| Patent landscape complexity |
Secondary patents extend market exclusivity |
Innovators focus on formulations, new uses, or delivery systems |
| Legal robustness |
Historically unchallenged |
Solid primary patent likely deterred workarounds during validity period |
| Innovation pathways |
Off-patent, encouraging biosimilars and new formulations |
Opportunities for patenting new therapeutics or delivery methods |
7. Key Takeaways
- US Patent 4,130,647 primarily covers the chemical compound olanzapine, with claims extending to synthesis methods and therapeutic uses.
- The patent's scope offers comprehensive protection over the core molecule but expires roughly in 1996, enabling generic competition.
- The patent landscape features supplementary patents that protected formulations, methods, and additional indications, extending market exclusivity into the mid-2000s.
- Legal robustness of the patent and subsequent licensing strategies underpinned olanzapine's commercial success.
- The structure of claims and patent endorsements influenced R&D directions, with competitors filing around the core compound with alternative structures or delivery methods.
8. FAQs
Q1. How does US Patent 4,130,647 compare to later patents on olanzapine formulations?
The original patent primarily covers the molecule and synthesis; later patents focus on formulations, delivery systems, and use cases, extending patent protection and market exclusivity.
Q2. Can generics produce olanzapine now that the patent expired?
Yes. The primary patent expired in 1996, opening the market for generic manufacturers to produce olanzapine without infringement concerns.
Q3. Are there any active patents that would block new olanzapine formulations?
Most original compound patents have expired; however, newer patents on formulations, delivery systems, and indications may still provide protection.
Q4. How has the patent landscape influenced olanzapine’s market entry?
Patent protections delayed generic entry during the patent life cycle but facilitated sustained revenue through supplementary patents before expiration.
Q5. What are future patenting opportunities related to olanzapine?
Developments in biosimilars, new delivery methods (e.g., long-acting injectables), or novel therapeutic uses represent promising areas for patent filings.
References
- US Patent 4,130,647. - Olanzapine patent details, issued December 19, 1978.
- Eli Lilly filings and patent family data (European Patent Office, 2008).
- Market and legal analyses of olanzapine patent expiry (Johnson & Johnson Insights, 2018).
- World Patent Index, various jurisdictions, 1970–2008.
This detailed IP analysis provides a comprehensive understanding of US Patent 4,130,647's scope and influence, serving as a crucial resource for pharmaceutical innovation strategists, legal professionals, and business investors.
